Dr. Michael Spigarelli

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) reported its unaudited interim financial results for the three and nine-month period ended September 30, 2022. PsyBio, a fully integrated and intellectual property-driven biotechnology company, develops new psycho-targeted therapies...

The current clinical scenario sets psilocybin as one of the most advanced psychedelics, expected to become legally approved in the US sometime between the 2023-2024 period and to become available as of January 2023 within local assisted therapy in Oregon. Now PsyBio Therapeutics Corp. (OTCQB: PSYBF...